MSD’s new pulmonary arterial hypertension (PAH) therapy Airwin (sotatercept) hit the Japanese market in mid-August. It’s the kind of launch…
BUSINESS
EMA Backs Leqembi after Re-Examination, but for Limited Use
The European Medicines Agency (EMA) has reversed its course on Eisai’s Alzheimer’s disease (AD) therapy Leqembi (lecanemab) and says it now recommends the drug’s approval, yet in a limited patient population. The EU regulator said on November 14 that its…
To read the full story
Related Article
- Austria, Germany Become First EU Markets to Launch Leqembi
August 26, 2025
- Eisai’s Alzheimer’s Drug Leqembi Now Approved in Europe
April 16, 2025
- Eisai Stands Firmly Behind Leqembi Profile despite EU Rejection
August 5, 2024
- EU Regulator Rejects Leqembi, Eisai to Seek Re-Examination
July 29, 2024
BUSINESS
- Nichi-Iko Shows Signs of Recovery but Restructuring Still Underway: CEO
September 5, 2025
- And Pharma Chief Pledges Growth Strategy as New Generics Holding Firm Takes Shape
September 5, 2025
- New Study of Vasomune-Partnered AV-001 Cleared in Canada: AnGes
September 5, 2025
- Keytruda Top-Selling Drug in Japan for 23 Months Running: Encise
September 5, 2025
- Eisai Begins FDA Rolling Submission for Leqembi SC for Starting Dose
September 4, 2025
Leftover stocks of high-priced medicines are emerging as a serious headache for Japanese pharmacies, fueling financial stress and even bankruptcies…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…